What is the half-life of glipizide (oral hypoglycemic agent) metabolism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Glipizide Metabolism Half-Life

Glipizide has a relatively short half-life of 2-4 hours in normal subjects after either intravenous or oral administration, with metabolism occurring rapidly and extensively in the liver. 1

Pharmacokinetic Profile of Glipizide

Absorption and Distribution

  • Gastrointestinal absorption is uniform, rapid, and essentially complete
  • Peak plasma concentrations occur 1-3 hours after a single oral dose
  • Protein binding is very high at 98-99% one hour after administration
  • Apparent volume of distribution is approximately 11 liters after intravenous administration 1

Metabolism

Glipizide undergoes extensive metabolism primarily in the liver:

  • The main metabolic pathways include:
    • Formation of inactive hydroxylation products
    • Creation of polar conjugates
  • Less than 10% of unchanged glipizide is found in the urine 1
  • The primary metabolites are pharmacologically inactive 2

Elimination

  • Half-life ranges from 2-4 hours in subjects with normal renal function 1
  • Some studies have reported a terminal elimination half-life range of 2-7 hours 3
  • Metabolites are excreted mainly in the urine 1

Clinical Implications of Glipizide's Short Half-Life

Dosing Considerations

  • Due to its short half-life, glipizide has a rapid onset of action
  • The insulinotropic response to a meal occurs within 30 minutes after an oral dose
  • Blood sugar control may persist in some patients for up to 24 hours despite the short half-life 1
  • Most effective when administered approximately 30 minutes before meals 1

Special Populations

  • Patients with renal impairment:

    • Glipizide is preferred over other sulfonylureas in patients with chronic kidney disease as it does not have active metabolites 4
    • However, dosage should be initiated conservatively to avoid hypoglycemia 4
    • Patients with renal impairment have a higher risk of developing severe hypoglycemia (odds ratio 4.0) 5
  • Elderly patients:

    • Elderly patients (mean age 75 years) are at higher risk for severe hypoglycemia 5
    • Careful dose adjustment is necessary in this population

Comparison to Other Sulfonylureas

  • Glipizide has a shorter duration of action compared to glibenclamide (glyburide) 2
  • Glyburide has a longer half-life of 7-10 hours compared to glipizide's 2-4 hours 3
  • Unlike first-generation sulfonylureas (chlorpropamide, tolazamide, tolbutamide), glipizide does not rely on the kidney to eliminate both parent drug and active metabolites 4

Practical Considerations

  • Despite its short half-life, glipizide can provide effective glycemic control with once or twice daily dosing
  • Careful monitoring is important when initiating therapy, particularly in elderly patients or those with renal impairment
  • Drug interactions should be considered, as patients taking multiple medications (particularly diuretics and benzodiazepines) have higher risk of hypoglycemia 5

In summary, glipizide is rapidly metabolized with a half-life of 2-4 hours, undergoes extensive hepatic metabolism to inactive metabolites, and is primarily excreted through the kidneys. This relatively short half-life contributes to its rapid onset of action but requires careful dosing to maintain glycemic control throughout the day.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Severe hypoglycaemia during treatment with glipizide.

Diabetic medicine : a journal of the British Diabetic Association, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.